Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review

Sara Mazzucco, Linxin Li, Peter M Rothwell, Sara Mazzucco, Linxin Li, Peter M Rothwell

Abstract

Importance: Patent foramen ovale (PFO) closure may prevent recurrent stroke after cryptogenic transient ischemic attack (TIA) or stroke (TIA/stroke) in patients aged 60 years or younger. Patent foramen ovale is associated with cryptogenic stroke in the older population, but risk of recurrence is unknown. Data on prognosis of patients receiving medical treatment at older ages (≥60 years) are essential to justify trials of PFO closure.

Objective: To examine the age-specific risk of recurrence in patients with cryptogenic TIA/stroke with PFO.

Design, setting, and participants: A prospective study was nested in the population-based Oxford Vascular Study between September 1, 2014, and March 31, 2019, with face-to-face follow-up for 5 years. A total of 416 consecutive patients with a diagnosis of cryptogenic TIA or nondisabling stroke, screened for PFO at a rapid-access TIA/stroke clinic, were included. A systematic review and meta-analysis of cohort studies reporting on ischemic stroke recurrence after cryptogenic TIA/stroke in patients with PFO who were receiving medical therapy alone, or with PFO vs no-PFO was conducted. Sample size calculation for future trials on PFO closure was performed for patients aged 60 years or older.

Exposures: Patent foramen ovale and age as modifiers of risk of recurrent stroke after cryptogenic TIA/stroke in patients receiving only medical therapy.

Main outcomes and measures: Risk of ischemic stroke recurrence in patients with cryptogenic TIA/stroke and PFO receiving medical therapy only, and in patients with vs without PFO, stratified by age (<65 vs ≥65 years), as well as sample-size calculation for future trials of PFO closure in patients aged 60 years or older.

Results: Among the 153 Oxford Vascular Study patients with PFO (mean [SD] age, 66.7 [13.7] years; 80 [52.3%] men), recurrent ischemic stroke risk (2.05 per 100 patient-years) was similar to the pooled estimate from a systematic review of 23 other studies (9 trials and 14 observational studies) (2.00 per 100 patient-years; 95% CI, 1.55-2.58). However, there was heterogeneity between studies (P < .001 for heterogeneity), owing mainly to risk increasing with mean cohort age (meta-regression: R2 = 0.31; P = .003). In the pooled analysis of 4 studies including patients with or without PFO, increased risk of stroke recurrence with PFO was seen only at age 65 years or older (odds ratio, 2.5; 95% CI, 1.4-4.2; P = .001 for difference; P = .39 for heterogeneity). The pooled ischemic stroke risk was 3.27 per 100 patient-years (95% CI, 2.59-4.13) in 4 cohorts with mean age 60 years or older. Assuming the more conservative 2.0 per 100 patient-years ischemic stroke risk in the PFO nonclosure arms of future trials in patients aged 60 years or older, projected sample sizes were 1080 per arm for 80% power to detect a 33% relative risk reduction.

Conclusions and relevance: The findings of this study suggest that age is a determinant of risk of ischemic stroke after cryptogenic TIA/stroke in patients with PFO, such that trials of PFO closure at older ages are justified; however, projected sample sizes are large.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Absolute Risk of Recurrent Ischemic…
Figure 1.. Absolute Risk of Recurrent Ischemic Stroke in Patients With Patent Foramen Ovale Receiving Medical Treatment Alone
OxVasc indicates Oxford Vascular Study. aRandomized trials. bAll recurrent strokes (ie, not recurrent ischemic strokes only).
Figure 2.. Meta-Regression Analysis Between Recurrent Ischemic…
Figure 2.. Meta-Regression Analysis Between Recurrent Ischemic Stroke Risk and Mean Study Age
Dotted circles represent the medical arm of patent foramen ovale closure trials.
Figure 3.. Risk of Ischemic Stroke Recurrence…
Figure 3.. Risk of Ischemic Stroke Recurrence After Cryptogenic Transient Ischemic Attack/Stroke in Patients With Patent Foramen Ovale (PFO) vs Patients Without PFO
OxVasc indicates Oxford Vascular Study.

References

    1. Carroll JD, Saver JL, Thaler DE, et al. ; RESPECT Investigators . Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092-1100. doi:10.1056/NEJMoa1301440
    1. Saver JL, Carroll JD, Thaler DE, et al. ; RESPECT Investigators . Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022-1032. doi:10.1056/NEJMoa1610057
    1. Mas JL, Derumeaux G, Guillon B, et al. ; CLOSE Investigators . Patent foramen ovale closure or anticoagulation vs antiplatelets after stroke. N Engl J Med. 2017;377(11):1011-1021. doi:10.1056/NEJMoa1705915
    1. Søndergaard L, Kasner SE, Rhodes JF, et al. ; Gore REDUCE Clinical Study Investigators . Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033-1042. doi:10.1056/NEJMoa1707404
    1. Lee PH, Song JK, Kim JS, et al. . Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO Trial. J Am Coll Cardiol. 2018;71(20):2335-2342. doi:10.1016/j.jacc.2018.02.046
    1. Mazzucco S, Li L, Binney L, Rothwell PM. Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. Lancet Neurol. 2018;17(7):609-617. doi:10.1016/S1474-4422(18)30167-4
    1. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357(22):2262-2268. doi:10.1056/NEJMoa071422
    1. Turc G, Calvet D, Guérin P, Sroussi M, Chatellier G, Mas JL; CLOSE Investigators . Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE Study. J Am Heart Assoc. 2018;7(12):e008356. doi:10.1161/JAHA.117.008356
    1. Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP; PICSS Investigators . Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke. 2004;35(9):2145-2149. doi:10.1161/01.STR.0000135773.24116.18
    1. Rothwell PM, Coull AJ, Giles MF, et al. ; Oxford Vascular Study . Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363(9425):1925-1933. doi:10.1016/S0140-6736(04)16405-2
    1. Li L, Yiin GS, Geraghty OC, et al. ; Oxford Vascular Study . Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015;14(9):903-913. doi:10.1016/S1474-4422(15)00132-5
    1. Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis. 2000;10(6):490-496. doi:10.1159/000016119
    1. Del Sette M, Dinia L, Rizzi D, Sugo A, Albano B, Gandolfo C. Diagnosis of right-to-left shunt with transcranial Doppler and vertebrobasilar recording. Stroke. 2007;38(8):2254-2256. doi:10.1161/STROKEAHA.106.479485
    1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. . Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. doi:10.1161/01.STR.24.1.35
    1. Liberati A, Altman DG, Tetzlaff J, et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700
    1. Thaler DE, Di Angelantonio E, Di Tullio MR, et al. . The Risk of Paradoxical Embolism (RoPE) Study: initial description of the completed database. Int J Stroke. 2013;8(8):612-619. doi:10.1111/j.1747-4949.2012.00843.x
    1. Mas JL, Zuber M; French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm . Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J. 1995;130(5):1083-1088. doi:10.1016/0002-8703(95)90212-0
    1. Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Metaanal. 2017;5(4):80-84. doi:10.13105/wjma.v5.i4.80
    1. McCullagh PNJ. Generalised Linear Models. Chapman and Hall; 1979.
    1. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed Blackwell Publishing; 2003.
    1. Béjot Y, Bailly H, Graber M, et al. . Impact of the ageing population on the burden of stroke: the Dijon Stroke Registry. Neuroepidemiology. 2019;52(1-2):78-85. doi:10.1159/000492820
    1. Danese A, Stegagno C, Tomelleri G, et al. ; Verostroke Group . Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale. Acta Cardiol. 2017;72(4):410-418. doi:10.1080/00015385.2017.1307668
    1. Nezu T, Kitano T, Kubo S, et al. . Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients. J Neurol. 2018;265(3):628-636. doi:10.1007/s00415-018-8742-x
    1. Weimar C, Holle DN, Benemann J, et al. ; German Stroke Study Collaboration . Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis. 2009;28(4):349-356. doi:10.1159/000229553
    1. Diener HC, Sacco RL, Easton JD, et al. ; RE-SPECT ESUS Steering Committee and Investigators . Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906-1917. doi:10.1056/NEJMoa1813959
    1. Meier B, Kalesan B, Mattle HP, et al. ; PC Trial Investigators . Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083-1091. doi:10.1056/NEJMoa1211716
    1. Furlan AJ, Reisman M, Massaro J, et al. ; CLOSURE I Investigators . Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991-999. doi:10.1056/NEJMoa1009639
    1. Kasner SE, Swaminathan B, Lavados P, et al. ; NAVIGATE ESUS Investigators . Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018;17(12):1053-1060. doi:10.1016/S1474-4422(18)30319-3
    1. Mas JL, Arquizan C, Lamy C, et al. ; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group . Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345(24):1740-1746. doi:10.1056/NEJMoa011503
    1. Serena J, Marti-Fàbregas J, Santamarina E, et al. ; CODICIA, Right-to-Left Shunt in Cryptogenic Stroke Study; Stroke Project of the Cerebrovascular Diseases Study Group, Spanish Society of Neurology . Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke. 2008;39(12):3131-3136. doi:10.1161/STROKEAHA.108.521427
    1. Moon J, Kang WC, Kim S, et al. . Comparison of outcomes after device closure and medication alone in patients with patent foramen ovale and cryptogenic stroke in Korean population. Yonsei Med J. 2016;57(3):621-625. doi:10.3349/ymj.2016.57.3.621
    1. Paciaroni M, Agnelli G, Bertolini A, et al. ; FORI (Foramen Ovale Registro Italiano) Investigators . Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovasc Dis. 2011;31(2):109-116. doi:10.1159/000321334
    1. Horner S, Niederkorn K, Gattringer T, et al. . Management of right-to-left shunt in cryptogenic cerebrovascular disease: results from the observational Austrian Paradoxical Cerebral Embolism Trial (TACET) registry. J Neurol. 2013;260(1):260-267. doi:10.1007/s00415-012-6629-9
    1. Harrer JU, Wessels T, Franke A, Lucas S, Berlit P, Klötzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci. 2006;33(1):39-47. doi:10.1017/S0317167100004674
    1. Lee JY, Song JK, Song JM, et al. . Association between anatomic features of atrial septal abnormalities obtained by omni-plane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol. 2010;106(1):129-134. doi:10.1016/j.amjcard.2010.02.025
    1. Wahl A, Jüni P, Mono ML, et al. . Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012;125(6):803-812. doi:10.1161/CIRCULATIONAHA.111.030494
    1. Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101(1):77-82. doi:10.1016/j.ijcard.2004.03.005
    1. Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34(1):74-80. doi:10.1017/S0317167100005825
    1. Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. Transcranial Doppler and risk of recurrence in patients with stroke and patent foramen ovale. Eur J Neurol. 2003;10(2):129-135. doi:10.1046/j.1468-1331.2003.00561.x
    1. Cerrato P, Priano L, Imperiale D, et al. . Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: a follow-up study. Neurol Sci. 2006;26(6):411-418. doi:10.1007/s10072-006-0524-z
    1. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999;15(1):57-64.
    1. Hanna JP, Sun JP, Furlan AJ, Stewart WJ, Sila CA, Tan M. Patent foramen ovale and brain infarct: echocardiographic predictors, recurrence, and prevention. Stroke. 1994;25(4):782-786. doi:10.1161/01.STR.25.4.782
    1. Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995;26(4):1030-1038. doi:10.1016/0735-1097(95)00288-9
    1. Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68(5):741-746. doi:10.1002/ccd.20868
    1. Shariat A, Yaghoubi E, Farazdaghi M, Aghasadeghi K, Borhani Haghighi A. Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: a randomized clinical trial. J Res Med Sci. 2013;18(2):94-98.
    1. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G; Lausanne Stroke with Paradoxal Embolism Study Group . Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology. 1996;46(5):1301-1305. doi:10.1212/WNL.46.5.1301
    1. Comess KA, DeRook FA, Beach KW, Lytle NJ, Golby AJ, Albers GW. Transesophageal echocardiography and carotid ultrasound in patients with cerebral ischemia: prevalence of findings and recurrent stroke risk. J Am Coll Cardiol. 1994;23(7):1598-1603. doi:10.1016/0735-1097(94)90662-9
    1. De Castro S, Cartoni D, Fiorelli M, et al. . Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31(10):2407-2413. doi:10.1161/01.STR.31.10.2407
    1. Eriksson SE. Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke: a 25-year follow-up hospital-based observational study. Brain Behav. 2016;7(1):e00603. doi:10.1002/brb3.603
    1. Faggiano P, Frattini S, Piovesana P, et al. . Low cerebrovascular event rate in subjects with patent foramen ovale and different clinical presentations: results from a prospective non randomized study on a population including patients with and without patent foramen ovale closure. Int J Cardiol. 2012;156(1):47-52. doi:10.1016/j.ijcard.2010.10.032
    1. Morais LA, Sousa L, Fiarresga A, et al. . RoPE score as a predictor of recurrent ischemic events after percutaneous patent foramen ovale closure. Int Heart J. 2018;59(6):1327-1332. doi:10.1536/ihj.17-489
    1. Putaala J, Nieminen T, Haapaniemi E, et al. . Undetermined stroke with an embolic pattern—a common phenotype with high early recurrence risk. Ann Med. 2015;47(5):406-413. doi:10.3109/07853890.2015.1057612
    1. Stone DA, Godard J, Corretti MC, et al. . Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J. 1996;131(1):158-161. doi:10.1016/S0002-8703(96)90065-4
    1. Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Dellborg M. Recurrent stroke in patients with patent foramen ovale: an observational prospective study of percutaneous closure of PFO versus non-closure. Int J Cardiol. 2015;195:293-299. doi:10.1016/j.ijcard.2015.05.088
    1. Elmariah S, Furlan AJ, Reisman M, et al. ; CLOSURE I Investigators . Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial. JACC Cardiovasc Interv. 2014;7(8):913-920. doi:10.1016/j.jcin.2014.01.170
    1. Furlan AJ; CLOSURE I Investigators . PFO closure: CLOSURE. Stroke. 2013;44(6)(suppl 1):S45-S47. doi:10.1161/STROKEAHA.113.000975
    1. Pezzini A, Grassi M, Lodigiani C, et al. ; Italian Project on Stroke in Young Adults (IPSYS) Investigators . Propensity score–based analysis of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale: the IPSYS Registry (Italian Project on Stroke in Young Adults). Circ Cardiovasc Interv. 2016;9(9):e003470. doi:10.1161/CIRCINTERVENTIONS.115.003470
    1. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators . Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105(22):2625-2631. doi:10.1161/01.CIR.0000017498.88393.44
    1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. . A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938. doi:10.1001/archinte.1991.00400050081016
    1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20. doi:10.1016/S0025-6196(12)60336-X
    1. Merkler AE, Gialdini G, Yaghi S, et al. . Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. Stroke. 2017;48(11):3073-3077. doi:10.1161/STROKEAHA.117.018501
    1. Emberson J, Lees KR, Lyden P, et al. ; Stroke Thrombolysis Trialists’ Collaborative Group . Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935. doi:10.1016/S0140-6736(14)60584-5
    1. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM; Carotid Endarterectomy Trialists Collaboration . Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363(9413):915-924. doi:10.1016/S0140-6736(04)15785-1
    1. Wiktor DM, Carroll JD. The case for selective patent foramen ovale closure after cryptogenic stroke. Circ Cardiovasc Interv. 2018;11(3):e004152. doi:10.1161/CIRCINTERVENTIONS.117.004152
    1. Mojadidi MK, Roberts SC, Winoker JS, et al. . Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt: a bivariate meta-analysis of prospective studies. JACC Cardiovasc Imaging. 2014;7(3):236-250. doi:10.1016/j.jcmg.2013.12.011

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa